A review based on a quick and heavily compromised cost-effectiveness evaluation conducted in secret with a threat to delist unless the company accepted a significant price reduction. Apparently, this is what constitutes a pricing negotiation in 2019. …
Latest Video
New Stories
-
New report highlights growing gene and cell therapy industry
January 24, 2020 - - Latest News -
Australian access behind comparable countries?
January 24, 2020 - - Latest News -
CSL Behring welcomes new presentations for genetic condition
January 24, 2020 - - Latest News -
Couple call on Jacinda Ardern to act on PHARMAC
January 24, 2020 - - Latest News -
Transparency of process is more important than transparency of outcome
January 23, 2020 - - Latest News -
CSL makes US-list of Best Employers for Diversity
January 23, 2020 - - Latest News -
AbbVie welcomes RINVOQ approval
January 23, 2020 - - Latest News